Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tau PET Imaging With 18F-T807 in Neurodegenerative Disorders
NCT04926259Phase 1Unknown
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Nov 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of flortaucipir in neurodegenerative diseases, sponsored by The First Hospital of Fujian Medical University. Primary endpoints: Standardized Uptake Value Ratio, Amyloid Beta 42 in Cerebrospinal Fluid and 4 more. Status: unknown.
02
Drugs
flortaucipir
03
Conditions
neurodegenerative diseases
Beyond the preview
Go deeper on NCT04926259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04926259.